Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

Cardiovascular Toxicology

Volumn 3, Issue 2, 2003, Pages 89-99

  Hasinoff, Brian B ^a   Schnabl, Kareena L ^a   Marusak, Rosemary A ^b   Patel, Daywin ^a   Huebner, Erwin ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b KENYON COLLEGE   (United States)

Author keywords

Antioxidant; Apoptosis; Cardiotoxicity; Dexrazoxane; Doxorubicin; Iron; Mitochondria; Myocyte; Oxygen radical

Indexed keywords

ANTIOXIDANT; DICHLOROFLUORESCEIN; DOXORUBICIN; DRUG METABOLITE; DYE; FLUORESCEIN; FLUORESCEIN ISOTHIOCYANATE; HYDROXYL RADICAL; LIPOCORTIN 5; PROPIDIUM IODIDE; RAZOXANE; SEMIQUINONE; CARDIOVASCULAR AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG APPROVAL; DRUG EFFICACY; DRUG HYDROLYSIS; EPIFLUORESCENCE MICROSCOPY; HEART MITOCHONDRION; HEART MUSCLE; HEART PROTECTION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STAINING; ANIMAL; CELL CULTURE; CELL MEMBRANE POTENTIAL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; HEART MUSCLE CELL; HEART VENTRICLE; IMAGE PROCESSING; INTRACELLULAR MEMBRANE; METABOLISM; NECROSIS; NEWBORN; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CARDIOVASCULAR AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; HEART VENTRICLES; IMAGE PROCESSING, COMPUTER-ASSISTED; INDICATORS AND REAGENTS; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; NECROSIS; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE; REACTIVE OXYGEN SPECIES;

EID: 0642280672     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:3:2:89     Document Type: Article

References (39)

1. Hasinoff, B.B., Hellmann, K., Herman, E.H., and Ferrans, V.J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 5:1-28.
2. Malisza, K.L. and Hasinoff, B.B. (1995). Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch. Biochem. Biophys. 321:51-60.
3. Barnabé, N., Zastre, J., Venkataram, S. and Hasinoff, B.B. (2002). Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med. 33:266-275.
4. Hasinoff, B.B. (1994). Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J. Pharm. Sci. 83:64-67.
5. Hasinoff, B.B. (1994). An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane) and its one-ring opened intermediates. Int. J. Pharmacol. 107:67-76.
6. Diop, N.K., Vitellaro, L.K., Arnold, P., Shang, M., and Marusak, R.A. (2000). Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J. Inorg. Biochem. 78:209-216.
7. Huang, Z.-X., May, P.M., Quinlan, K.M., Williams, D.R., and Creighton, A.M. (1982). Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12:536-542.
8. Buss, J.L. and Hasinoff, B.B. (1993). The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40:86-95.
9. Dawson, K.M. (1975). Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 24:2249-2253.
10. Jung, K. and Reszka, R. (2001). Mitochondria as subcellular targets for clinically useful anthracyclines. Adv. Drug Deliv. Rev. 49:87-105.
11. Hershko, C., Pinson, A., and Link, G. (1996). Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematol. 95:87-92.
12. 2+ from rat heart mitochondria. Biochem. Pharmacol. 37:803-812.
13. Gianni, L., Corden, B.J. and Myers, C.E. (1983). The biochemical basis of anthracycline toxicity and anti-tumor activity. Rev. Biochem. Toxicol. 5:1-82.
14. Hasinoff, B.B. and Davey, J.P. (1988). Adriamycin and its iron(III) and copper(II) complexes; glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin. Biochem. Pharmacol. 37:3663-3669.
15. Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., and Ruysschaert, J.-M. (1990). Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys. Chem. 35:247-257.
16. Reers, M., Smiley, S.T., Mottola-Hartshorn, C., Chen, A., Lin, M., and Chen, L.B. (1995). Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol. 260:406-417.
17. Keij, J.F., Bell-Prince, C., and Steinkamp, J.A. (2000). Staining of mitochondrial membranes with 10-nonyl acridine orange, MitoFluor Green, and MitoTracker Green is affected by mitochondrial membrane potential altering drugs. Cytometry 39:203-210.
18. Swift, L.M. and Sarvazyan, N. (2000). Localization of dichlorofluorescin in cardiac myocytes: Implications for assessment of oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 278:H982-H990.
19. Sarvazyan, N. (1996). Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am. J. Physiol. 271:H2079-H2085.
20. Link, G., Tirosh, R., Pinson, A., and Hershko, C. (1996). Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127:272-278.
21. Childs, A.C., Phaneuf, S.L., Dirks, A.J., Phillips, T., and Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 62:4592-4598.
22. Kluck, R.M., Bossy-Wetzel, E., Green, D.R., and Newmeyer, D.D. (1997). The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136.
23. Dunkern, T.R. and Mueller-Klieser, W. (1999). Quantification of apoptosis induction by doxorubicin in three types of human mammary carcinoma spheroids. Anticancer Res. 19:3141-3146.
24. Sawyer, D.B., Fukazawa, R., Arstall, M.A., and Kelly, R.A. (1999). Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 84:257-265.
25. Kumar, D., Kirshenbaum, L., Li, T., Danelisen, I., and Singal, P. (1999). Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann. N. Y. Acad. Sci. 874:156-168.
26. Kotamraju, S., Konorev, E.A., Joseph, J., and Kalyanaraman, B. (2000). Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. 275:33585-33592.
27. Hasinoff, B.B. (2002). Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol. 2:111-118.
28. Malisza, K.L. and Hasinoff, B.B. (1996). Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Free Radicals Biol. Med. 20:905-914.
29. LeBel, C.P., Ischiropoulos, H., and Bondy, S.C. (1992). Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 5:227-231.
30. Rota, C., Chignell, C.F., and Mason, R.P. (1999). Evidence for free radical formation during the oxidation of 2′-7′-dichlorofluorescin to the fluorescent dye 2′-7′-dichlorofluorescein by horseradish peroxidase: possible implications for oxidative stress measurements. Free Radicals Biol. Med. 27:873-881.
31. Kang, Y.J., Zhou, Z.X., Wang, G.W., Buridi, A., and Klein, J.B. (2000). Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 275:13690-13698.
32. Davies, K.J.A. and Doroshow, J.H. (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261:3060-3067.
33. Myers, C.E., Mimnaugh, E.G., Yeh, G.C., and Sinha, B.K. (1988) Biochemical mechanisms of tumor cell kill by the anthracyclines. In Lown, J.W. (ed.), Anthracycline and Anthracenedione-based Anticancer Agents, vol. 6. Amsterdam: Elsevier, pp. 527-569.
34. Hochster, H., Liebes, L., Wadler, S., Oratz, R., Wernz, J.C., Meyers, M., Green, M., Blum, R.H., and Speyer, J.L. (1992). Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84:1725-1730.
35. Zhang, J., Clark, J.R., Herman, E.H., and Ferrans, V.J. (1996). Doxorubicin-induced apoptosis in spontaneously hypertensive rats: Differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J. Mol. Cell. Cardiol. 28:1931-1943.
36. Herman, E.H., Zhang, J., Hasinoff, B.B., Clark, J.R.J., and Ferrans, V.J. (1997). Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J. Mol. Cell. Cardiol. 29:2415-2430.
37. Hasinoff, B.B. (1993). Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab. Dispos. 21:883-888.
38. Schroeder, P.E., Davidson, J.N., and Hasinoff, B.B. (2002). Dihydroorotase catalyzes the ring-opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab. Dispos. 30:1431-1435.
39. Schroeder, P.E., and Hasinoff, B.B. (2002). The doxorubicin- cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother. Pharmacol. 50:509-513.